Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catrin Pritchard

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Genes & Development|August 16, 2012
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathwayCatherine Andreadi, Lai-Kay Cheung, Susan Giblett, et al.
Pigment Cell & Melanoma Research|December 17, 2009
Inducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethalityNathalie Dhomen, Silvy Da Rocha Dias, Robert Hayward, et al.
Cell|February 10, 2010
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAFSonja J Heidorn, Carla Milagre, Steven Whittaker, et al.
Analytical Chemistry|June 18, 2020
Exploration of Matrix Effects in Laser Ablation Inductively Coupled Plasma Mass Spectrometry Imaging of Cisplatin-Treated TumorsCalum J Greenhalgh, Ellie Karekla, Gareth J Miles, et al.
Heliyon|January 4, 2019
Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERKFiona Hey, Catherine Andreadi, Catherine Noble, et al.
Cancer Research|March 1, 2017
<i>Cyp24a1</i> Attenuation Limits Progression of <i>Braf<sup>V600E</sup></i> -Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAF<sup>V600E</sup> Inhibitor PLX4720Minjing Zou, Essa Y Baitei, Huda A BinEssa, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 2002
MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gammaSanjit K Roy, Junbo Hu, Qingjun Meng, et al.
Cellular Oncology (Dordrecht, Netherlands)|February 3, 2021
Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non-medullary thyroid cancerThomas Crezee, Marika H Tesselaar, James Nagarajah, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2011
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in miceAime T Franco, Roberta Malaguarnera, Samuel Refetoff, et al.
Oncotarget|November 21, 2017
Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancerPatricia Adamo, Caroline M Cowley, Christopher P Neal, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Genes & Development|August 16, 2012
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathwayCatherine Andreadi, Lai-Kay Cheung, Susan Giblett, et al.
Pigment Cell & Melanoma Research|December 17, 2009
Inducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethalityNathalie Dhomen, Silvy Da Rocha Dias, Robert Hayward, et al.
Cell|February 10, 2010
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAFSonja J Heidorn, Carla Milagre, Steven Whittaker, et al.
Analytical Chemistry|June 18, 2020
Exploration of Matrix Effects in Laser Ablation Inductively Coupled Plasma Mass Spectrometry Imaging of Cisplatin-Treated TumorsCalum J Greenhalgh, Ellie Karekla, Gareth J Miles, et al.
Heliyon|January 4, 2019
Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERKFiona Hey, Catherine Andreadi, Catherine Noble, et al.
Cancer Research|March 1, 2017
<i>Cyp24a1</i> Attenuation Limits Progression of <i>Braf<sup>V600E</sup></i> -Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAF<sup>V600E</sup> Inhibitor PLX4720Minjing Zou, Essa Y Baitei, Huda A BinEssa, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 2002
MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gammaSanjit K Roy, Junbo Hu, Qingjun Meng, et al.
Cellular Oncology (Dordrecht, Netherlands)|February 3, 2021
Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non-medullary thyroid cancerThomas Crezee, Marika H Tesselaar, James Nagarajah, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2011
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in miceAime T Franco, Roberta Malaguarnera, Samuel Refetoff, et al.
Oncotarget|November 21, 2017
Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancerPatricia Adamo, Caroline M Cowley, Christopher P Neal, et al.
Pageof 6